3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Leukemia, Myeloid, Acute
4
Breast Neoplasms
4
Lung Neoplasms
3
Neoplasm Metastasis
2
Tissue Adhesions
1
Solid Tumor Refractory to Standard Therapy
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Platinum Resistant Ovarian Cancer
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Ototoxicity
1
Neutropenia
1
Neoplasms
1
Myoma
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphopenia
1
Locally Advanced Cervical Cancer
1
Limited Stage Small Cell Lung Cancer
1
Leiomyoma
1
Hearing Loss
1
Febrile Neutropenia
1
Fatigue
1
Interventions
pegylated granulocyte colony-stimulating factor
3
pegfilgrastim
3
Vancomycin
3
Linezolid
2
Filgrastim
2
ceftolozane, tazobactam drug combination
1
Teicoplanin
1
Sodium Chloride
1
Piperacillin, Tazobactam Drug Combination
1
N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
1
Meropenem
1
Itraconazole
1
Cefepime
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Febrile Neutropenia
×
Sodium Chloride
×
Clear all
NCT01619423
2018-07-06
PLIANT
Egetis Therapeutics
Phase 1/2
Completed
186 enrolled
12 charts